Related Experiment Video
Updated: Jul 10, 2026
08:15
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
Published on: September 17, 2015
A perspective on telmisartan and cardiovascular risk
1Division of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Reviews in Cardiovascular Medicine
|October 17, 2007
Summary
Angiotensin receptor blockers (ARBs) like telmisartan effectively lower blood pressure. Ongoing trials are investigating ARBs
Area of Science:
- Cardiovascular medicine
- Pharmacology
Background:
- Angiotensin receptor blockers (ARBs) are established treatments for arterial hypertension.
- Telmisartan is an ARB known for potent blood-pressure lowering effects and a long half-life.
- Current research is exploring the benefits of ARBs in high-risk patient populations.
Purpose of the Study:
- To examine the benefits of ARBs, specifically telmisartan, in high-risk patients.
- To evaluate ARBs alone and in combination with angiotensin-converting enzyme (ACE) inhibitors.
- To assess the efficacy of telmisartan in sustaining blood pressure reduction.
Main Methods:
- Utilizing data from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET).
- Analyzing results from the Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant Subjects with Cardiovascular Disease (TRANSCEND) trial.
- Comparing ARBs with ACE inhibitors in specific patient cohorts.
Main Results:
- Telmisartan demonstrates potent blood-pressure lowering effects.
- The long half-life of telmisartan supports sustained blood pressure reduction.
- ARBs have not yet demonstrated a reduction in mortality and morbidity in high-risk patients without heart failure.
Conclusions:
- ARBs, including telmisartan, are effective antihypertensives.
- Further research is ongoing to define the role of ARBs in reducing cardiovascular events in high-risk individuals.
- Telmisartan's pharmacokinetic profile is advantageous for consistent blood pressure control.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...